Extended Fig. 8c

B16F10 cells expressing MICA*001 were engrafted, s.c., into C57BL/6 mice. 4 days later, when tumors reach 150 mm³, mice were randomized to six groups and treated once weekly for three consecutive weeks with 0.1 mg/kg, 0.25 mg/kg or 0.5 mg/kg MICAB1 PBD1G-ADCs or IC-PBD1G.<b> </b>Kaplan–Meier curves showing mouse survival (<i>n</i>=12 per group). Mantel-Cox test, **** p&lt;0.0001 (0.5 mg/kg and 0.25 mg/kg) and ***p&lt;0.001 (0.1mg/kg). Right panels: Cured mice (<i>n</i>=9) and naïve mice (<i>n</i>=10) were re-challenged s.c. with B16F10 expressing MICA*001 on one flank and B16F10 wt cells in the opposite flank. Some cured mice (<i>n</i>=4) were not re-challenged and monitored for eventual tumor regrowth